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Commonly observed aberrations in epidermal growth factor receptor (EGFR) signaling have led to the development
of EGFR-targeted therapies for various cancers, including non–small cell lung cancer (NSCLC). EGFR mutations and
overexpression have further been shown to modulate sensitivity to these EGFR-targeted therapies in NSCLC and several
other types of cancers. However, it is clear that mutations and/or genetic variations in EGFR alone cannot explain all of
the variability in the responses of patients with NSCLC to EGFR-targeted therapies. For instance, in addition to EGFR
genotype, genetic variations in other members of the signaling pathway downstream of EGFR or variations in parallel
receptor tyrosine kinase (RTK) pathways are now recognized to have a significant impact on the efficacy of certain
EGFR-targeted therapies. In this review, we highlight the mutations and genetic variations in such genes downstream
of EGFR and in parallel RTK pathways. Specifically, the directional effects of these pharmacogenetic factors are discussed
with a focus on two commonly prescribed EGFR inhibitors: cetuximab and erlotinib. The results of this comprehensive
review can be used to optimize the treatment of NSCLC with EGFR inhibitors. Furthermore, they may provide the
rationale for the design of subsequent combination therapies that involve the inhibition of EGFR.
Keywords: Pharmacogenomics, Non–small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR),
Cetuximab, ErlotinibIntroduction
Non–small cell lung cancer (NSCLC) accounts for
nearly 80% of all lung cancers and is the leading cause of
cancer-related deaths worldwide [1,2]. Moreover, late-
stage detection limits the treatment options for many pa-
tients with NSCLC given that most cancers have already
metastasized at the time of diagnosis [1]. In more than
one half of all patients with NSCLC, the aberrant epider-
mal growth factor receptor (EGFR) signaling contributes
to the oncogenic phenotype [1]. More recent attempts to
treat NSCLC have thus focused on targeting EGFR in
order to abrogate the oncogenic signaling mediated by
activating EGFR mutations (found in approximately 15%
of patients with NSCLC), EGFR overexpression, and/or
EGFR gene copy number enhancement [3-5]. For ex-
ample, EGFR inhibition is achieved through two main
classes of drugs: tyrosine-kinase inhibitors (TKIs) and* Correspondence: rhuang@medicine.bsd.uchicago.edu
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stated.monoclonal antibodies. Cetuximab (Erbitux™) is a com-
monly prescribed monoclonal antibody for the treat-
ment of metastatic NSCLC. Cetuximab inhibits EGFR
by binding to its extracellular domain, which then
blocks ligand-dependent receptor activation [6]. Although
less clearly understood, cetuximab also inhibits EGFR sig-
naling by mediating receptor endocytosis and degradation
and thus it also decreases ligand-independent EGFR
signaling [7]. On the contrary, erlotinib (Tarceva™) is a fre-
quently prescribed TKI for the treatment of NSCLC. By
binding to the intracellular kinase domain of EGFR at the
ATP-binding site, erlotinib inhibits kinase activity by
blocking ATP hydrolysis [1,8-10].
Pharmacogenomic studies have shown that EGFR
mutation status is associated with erlotinib efficacy and
that EGFR overexpression is associated with patient
response to cetuximab and other EGFR-targeted agents
[1,11-13]. However, even among patients who are se-
lected for specific treatments based on their somatic
EGFR mutation status or EGFR expression profile, there
remains a notable lack of response to EGFR-targeted ther-
apies in a significant portion of the patient population. Forl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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activating EGFR mutations do not respond as expected to
TKIs against EGFR [1,14]. Therefore, although EGFR sta-
tus is still an important indicator of patient response to
EGFR-targeted therapies, it is clearly not the only gene
that influences the therapeutic response. A review of the
pharmacogenomics of cetuximab and erlotinib instead re-
veals that other genetic factors, beyond EGFR, influence
the efficacy of these agents and can potentially guide the
treatment of NSCLC with mutant EGFR or EGFR overex-
pression. In fact, cetuximab serves as a model candidate
drug with which to explore the effects of such non-EGFR
genetic variations on the treatment of NSCLC given the
established association between Kirsten rat sarcoma
viral oncogene (KRAS) mutations and poor efficacy of
cetuximab in the treatment of colorectal cancer [15].
Similar non-EGFR genetic variations have been impli-
cated in modulating erlotinib efficacy in those patients
with NSCLC who harbor activating EGFR mutations
[1,16,17]. More specifically, recent and compelling evi-
dence now suggests that genetic variations in other
members of the signaling pathway downstream of
EGFR, and also in the non-EGFR receptor tyrosine kin-
ase (RTK) pathways, can influence responses to cetuxi-
mab and erlotinib.
The EGFR signaling network
EGFR signaling contributes to the regulation of funda-
mental biological processes including cell proliferation,
differentiation, survival, adhesion, homeostasis, and
tumorigenesis [18-21]. Exceedingly complex and highly
regulated signal transduction mechanisms are required
to govern such varied EGFR responses to external stim-
uli [19,20,22]. Given the vast complexity of the EGFR
signaling network, it is hardly surprising that genetic
factors beyond EGFR mutations or variable expression
patterns may modulate therapeutic responses to EGFR-
targeted agents. Here, we present an overview of EGFR
signaling and highlight the primary downstream signal-
ing pathways (Figure 1).
EGFR is a membrane-spanning cell surface receptor and
consequently links internal signaling pathways to the
extracellular environment [19]. When stimulated by extra-
cellular ligand binding, EGFR can initiate intracellular
kinase cascades through its intracellular tyrosine kinase
domain (Figure 1) [18,19]. In humans, 7 peptide growth
factors function as EGFR ligands, among which the ca-
nonical ligand is epidermal growth factor (EGF) [18,21].
These ligands can either be membrane-bound to adjacent
cells or soluble if they undergo proteolysis at the cell
membrane, which allows EGFR to integrate stimuli from a
variety of local and distant sources (Figure 1) [21,23].
Structurally, EGFR has a domain architecture that con-
sists of four extracellular domains, one transmembranedomain, one juxtamembrane domain, and one tyrosine
kinase domain followed by a flexible C-terminal tail
(Figure 1) [24]. Prior to ligand binding, EGFR exists as a
catalytically inactive monomer in the cell membrane
[19,24]. Following bivalent ligand binding to a single
EGFR molecule, the receptor changes conformation to
facilitate dimerization and activation [18,19,24]. Recep-
tor activation then proceeds through a defined series of
auto and transphosphorylation events between the
kinase domains in the EGFR dimer [19]. The activated
kinases further proceed to phosphorylate the C-terminal
tail regions on the neighboring receptor, creating phos-
phorylated tyrosine (pY) residues [19,25]. The pY residues
then serve as docking sites for proteins that are capable
of binding pY motifs (Figure 1) [19,20,26]. The docked
proteins can then either transduce intracellular signals
following direct phosphorylation by EGFR or initiate
higher-order signaling cascades through scaffolding and
localization mechanisms (Figure 1) [19,27,28].
Once activated, EGFR transduces its numerous cellular
responses through three primary signaling cascades: the
mitogen–activated protein kinase (MAPK) pathway, the
phosphoinositide 3-kinase/protein kinase B (PI3K/AKT)
pathway, and the Janus kinase/signal transducer and ac-
tivator of transcription (JAK/STAT) pathway (Figure 1)
[1,18,25]. Notably, these three central signaling path-
ways, although downstream of EGFR, are also activated
by almost every other RTK (Figure 1) [19,29]. Once
EGFR activates the rat sarcoma (RAS) family of proteins,
the MAPK pathway proceeds through the consecutive
phosphorylation of rapidly accelerated fibrosarcoma
(RAF), MAPK kinase (MEK), and MAPK via the recruit-
ment of the son of sevenless/growth factor receptor-
bound protein 2 (SOS/GRB2) complex (Figure 1) [18,30].
The MAPK cascade results in the activation of various
transcription factors, which act to alter cellular expression
profiles and to promote proliferation (Figure 1) [30]. The
PI3K/AKT pathway not only governs the anti-apoptotic
and pro-survival signals associated with EGFR activation
but also plays a role in the regulation of cell growth via
the activation of the mammalian target of rapamycin
(mTOR) (Figure 1) [1,31]. Moreover, AKT activation
promotes the accumulation of nuclear factor-kappa B
(NF-κB) in the nucleus, which further promotes cell
survival [32]. The PI3K/AKT pathway is also negatively
regulated by phosphatase and tensin homolog (PTEN),
a phosphatase that opposes PI3K activity to repress
AKT activation (Figure 1) [33]. JAK/STAT signaling is
initiated when proteins of the JAK family are recruited
to EGFR and are activated via phosphorylation [34]. Ac-
tivated JAK proteins can phosphorylate proteins of the
STAT family, which then dimerize, translocate to the
nucleus, and enact global cellular effects, particularly
those related to cell survival and proliferation (Figure 1)
Figure 1 Schematic representation of the primary epidermal growth factor receptor (EGFR) signaling pathway. During normal EGFR
signaling, receptor activation is dependent on ligand-mediated receptor dimerization. Once the subunits dimerize, a series of phosphorylation
events serve to enhance EGFR kinase activity to stimulate the activation of downstream targets. Downstream signals are propagated by EGFR
through three central pathways via both the direct phosphorylation of downstream targets (the JAK/STAT pathway) and the membrane recruitment of
key adaptor proteins (the PI3K/AKT and MAPK pathways) to promote cell survival and proliferation. The EGFR signaling through a conserved core of
three downstream signaling pathways demonstrates how the activation of this pathway via parallel RTKs, such as HER2, HER3, and MET, can circumvent
the inhibitory effects of cetuximab and erlotinib on EGFR. EGFR, epidermal growth factor receptor; JAK/STAT, Janus activated kinase/signal transducer
and activator of transcription; PI3K/AKT, phosphoinositide 3-kinase/protein kinase B; MAPK, mitogen-activated protein kinase; HER2, human epidermal
growth factor receptor 2; HER3, human epidermal growth factor receptor 3; MET, hepatocyte growth factor receptor; SOS, son of sevenless;
GRB2, growth factor receptor-bound protein 2; RAS, rat sarcoma family of proteins; RAF, rapidly accelerated fibrosarcoma; MEK, MAPK kinase;
PTEN, phosphatase and tensin homolog; mTOR, mammalian target of rapamycin; FOXO, forkhead box proteins; NF-κB, nuclear factor-kappa B.
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reveal the oncogenic potential of aberrant EGFR signaling.
Review
Erlotinib and cetuximab as EGFR-targeted therapeutics in
NSCLC: pharmacogenomics of EGFR
The genetic variation in EGFR and how this variation
alters typical EGFR signaling, plus its effects on cetuximab
and erlotinib efficacy, have all been extensively reviewedelsewhere [1,35,36]. However, it is important to briefly
describe the genetic variations in EGFR in order to provide
a framework for the interpretation of how non-EGFR
genetic variations can affect responses to cetuximab and
erlotinib; namely, aberrant activation of signaling pathways
downstream of, or parallel to, the EGFR signaling network
can compensate for EGFR inhibition. On the most basic
level, two types of genetic variations in EGFR drive hyper-
active signaling: constitutive activation and overexpression
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either point mutations in the kinase domain or larger dele-
tions in the juxtamembrane domain that relieve the auto-
inhibition of the ligand-free monomer [1,19,36,37]. Thus,
even in the absence of ligand, these receptors are active
and continually promote downstream signaling. EGFR
overexpression is another mechanism that contributes to
hyperactive EGFR signaling. The observed increase in sig-
naling strength from EGFR overexpression is partly due to
the increase in the number of receptors, which amplify the
downstream signaling effects [1,36,38]. In addition, the
overexpression of wild-type (wt)-EGFR can promote rogue
signaling through a ligand-free activation mechanism
comparable to that of mutant EGFR. Specifically, the in-
creased local concentration of EGFR at the cell membrane
can increase the stochastic, ligand-free dimerization of
EGFR that activates the receptors [39].
Unlike newer TKIs that irreversibly bind to EGFR, er-
lotinib reversibly binds to the ATP-binding pocket of
EGFR and inhibits catalytic activity via the prevention of
ATP-dependent activation of downstream targets [8,40].
Moreover, erlotinib is very similar to gefitinib, another
commonly studied EGFR TKI, in that they have similar
mechanisms of action and have been demonstrated to
have similar effectiveness in the treatment of NSCLC,
despite reports of minor differences in toxicity [41,42].
Given its mechanisms of action and the prerequisite of
ATP hydrolysis for EGFR catalytic activity, erlotinib was
predicted to elicit a positive drug response in patients
with NSCLC as long as they were positive for EGFR
expression, regardless of the EGFR mutation status.
However, a wealth of research has been conducted that
suggests that only certain activating mutations in EGFR
serve as positive clinical indicators for the use of erloti-
nib in patients with NSCLC [25,43-46]. Surprisingly, it
has been demonstrated that while several mutations in
EGFR confer a susceptibility to erlotinib, others facilitate
the opposite effect—a resistance to erlotinib [47-49].
The most common activating mutations in EGFR, which
account for 90% of all EGFR mutations in cases of
NSCLC, are exon 19 deletions and the L858R mutation
in the tyrosine kinase domain (Table 1) [1]. Other point
mutations such as G719C, G719S, G719A, and L861Q
similarly result in mutant forms of EGFR that are hyper-
active (Table 1) [1]. Importantly, all of these activating
mutations have been shown to incur sensitivity to EGFR
TKIs such as erlotinib (Table 1) [1]. Other activating
EGFR mutations, primarily in exon 20, such as T790M
(gatekeeper mutation), L747S, D761Y, and T854A, also
result in overactive EGFR signaling but instead grant
resistance to erlotinib and other TKIs that are similar
to erlotinib [1,48,50,51]. More importantly, given their
association with acquired TKI resistance, these muta-
tions appear to overrule the normal erlotinib sensitivityincurred by the more common EGFR-activating muta-
tions when both mutation types are concurrently present
(Table 1) [1,48]. As a consequence, several irreversible
potent anti-EGFR agents have either been approved by
the United States Food and Drug Administration (FDA)
(e.g., afatinib) or show promise in clinical trials to over-
come the T790M-mediated EGFR TKI resistance [52-55].
The variability in the response to erlotinib in the treat-
ment of NSCLC is further accentuated by the fact that
only approximately 10% of patients without activating
EGFR mutations demonstrate a drug response to first-line
erlotinib treatment [1,56-58]. Clearly, the gene-drug rela-
tionship of EGFR and erlotinib is dependent upon more
than EGFR mutation status alone, and these findings sug-
gest the need to elucidate the predictive value of other
specific, non-EGFR genetic variants that could guide the
treatment of NSCLC.
Some studies suggest that the response to erlotinib is
also improved in patients with EGFR overexpression
[1,59]. However, this association might be due to the link
between the efficacy of erlotinib and EGFR mutation sta-
tus because activating EGFR mutations often promote
increased expression and altered copy number of EGFR.
Moreover, other studies have provided contrary evidence
with regard to the association between EGFR expression
and benefits from erlotinib treatment [1]. Unlike erloti-
nib, cetuximab has an efficacy that has been associated
with high levels of EGFR (mutant or wild-type) expres-
sion but not with EGFR mutations or copy number vari-
ation (Table 1) [11,13]. Variation in EGFR expression
alone, though, is not sufficient to explain the pharmaco-
genomics of cetuximab in the treatment of NSCLC. For
example, one trial evaluated the expression of immu-
nohistochemically detectable EGFR as a biomarker, and
recruited patients to examine the effectiveness of cetu-
ximab in combination with first-line chemotherapy
[60,61]. The trial showed that standard chemotherapy
plus cetuximab was superior to chemotherapy alone in
patients whose tumors expressed EGFR [60,61]. In con-
trast to these findings, the analysis of a similar trial that
lacked patient selection based on EGFR expression sta-
tus found no association of EGFR expression status with
cetuximab benefit; however, this study confirmed that
EGFR mutation status and gene copy number are not
predictive biomarkers of the response to cetuximab
treatment [60-63]. Despite these inconsistencies, a meta-
analysis of 4 such trials has provided evidence that a
high level of EGFR expression can predict clinical bene-
fits from cetuximab therapy [13]. Therefore, unlike
EGFR mutation status for erlotinib, the most appropriate
biomarker for the selection of patients with NSCLC for
cetuximab treatment appears to be the expression level
of EGFR. However, further studies are still needed to
corroborate these findings given the debate over the
Table 1 Pharmacogenomics of cetuximab and erlotinib: potential biomarkers that are predicative of drug efficacy
Biomarker Cetuximab Erlotinib
EGFR biomarkers
EGFR Expression profile that incurs sensitivity: Mutations that incur sensitivity [1]:
♦High EGFR expression (as determined by IHC




♦G719X (X = C, S, or A)
♦L861Q
Expression profile that incurs resistance: Mutations that incur resistance (primarily exon 20
insertions) [1]:






Biomarkers in downstream components of the EGFR signaling




PIK3CA Mutations that incur resistance (in colorectal
cancer and human head and neck cancer)
Activating mutations that incur resistance [72,73,76]
Exon 20 kinase domain mutations: Exon 9 helical domain mutations:
♦H1047X (primarily H1047R) [77-79] ♦E542X (primarily E542K)
♦E545X (primarily E545K)
Exon 20 kinase domain mutation:
♦H1047X (primarily H1047R)
PTEN Mutations that incur resistance: Mutations that incur resistance [80]:
♦Homozygous PTEN deletions ♦Homozygous PTEN deletions
♦Missense/loss of function mutations [114] ♦Missense/loss of function mutations
Expression profile that incurs resistance: Expression profile that incurs resistance:
♦Low/null PTEN expression [81,82]
♦Null PTEN expression [83,84] Expression profile that incurs sensitivity:
♦High PTEN expression [81]
NF-κB Expression profile that incurs sensitivity: Factors that enhance sensitivity:
♦Low NF-κB (as determined by evidence
from patients with colorectal cancer [88])
♦Low NF-κB expression (via knockdown of RELA
subunit) [87]
Expression profile that incurs resistance: ♦Inactive NF-κB associated with increased inhibitor
of NF-κB (NFKBIA) expression [87]
♦High NF-κB (as determined by evidence
from patients with colorectal cancer [88])
Factors that enhance resistance:
♦High NF-κB (as determined by NF-κB overexpression)
♦Overactive NF-κB (via NFKBIA knockdown [87], IKK
overexpression [87], and high levels of AEG-1 [1])
Biomarkers in other RTKs
MET Incurred resistance from: Incurred resistance from:
♦MET amplification [98] ♦MET gene amplification [92,93,96]
♦MET activation [98,99] ♦Enhanced MET signaling dependent on HER3 [97]
♦Increased concentrations of HGF ligand [94]
HER2 Incurred resistance from: Incurred resistance from:
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(Continued)
♦Enhanced copy number of HER2 gene [103] ♦Enhanced copy number of HER2 gene [103]
♦HER2-mediated signaling [101,103] ♦Activating HER2 mutations in exons 18–21
(kinase domain), notably 12-bp duplication/
insertion of YVMA in exon 20 at codon 776
(HERYVMA) [103]
HER3 Incurred resistance from: Incurred sensitivity from:
♦Enhanced EGFR/HER3 activity via up-regulated
HER3 [101]
♦Low HER3 expression [115]
♦Dimerization and transactivation of HER2/3 in
an EGFR-dependent manner [101]
♦Down-regulation of HER3 by RNAi in EGFR-mutant
and wild-type EGFR cell lines [97]
Restored sensitivity from:
♦Down-regulation of HER3 by siRNA [101]
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PTEN,
phosphatase and tensin homolog; NF-κB, nuclear factor kappa-B; RTK, receptor tyrosine kinase; MET, hepatocyte growth factor receptor; HER2/3, human epidermal
growth factor receptor 2/3; siRNA, small interfering RNA; IHC, immunohistochemistry; NSCLC, non–small cell lung cancer; RELA, rel homology domain A; NFKBIA,
nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alpha; IKK, IκB kinase; AEG-1, astrocyte elevated gene-1; HGF, hepatocyte growth factor;
RNAi, RNA interference.
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several studies still question the predictive value of the
expression level of EGFR in the treatment of patients
with NSCLC [6,64,65].
Pharmacogenomics beyond EGFR: downstream pathway
members
Clear pharmacogenomic associations exist between cetux-
imab and erlotinib and genes other than EGFR. Some of
the most well-characterized associations involve genetic
variations in downstream pathway members in the EGFR
signaling network. Given that the signaling pathways that
are activated by EGFR primarily consist of kinase phos-
phorylation cascades, it is not surprising that mutations in
these kinases are similar to those that result in the consti-
tutive activation of EGFR. As shown in Figure 1, EGFR
regulates numerous signaling pathways after activation
and thus mutations in any downstream pathway member
could foreseeably compensate for EGFR inhibition via
the overstimulation of a specific node of downstream
signaling.
Prime examples of genetic variation in signaling pro-
teins downstream of EGFR are KRAS mutations (Table 1)
[1,16]. KRAS mutations have been linked to the reduced
efficacy of erlotinib in the treatment of NSCLC and to
that of cetuximab in the treatment of colorectal cancer
[1,15,17]. Moreover, evidence from other RTK-targeted
TKIs suggests that mutations in KRAS are highly associ-
ated with intrinsic resistance to TKI treatment [1,17].
For instance, one study found that 95% of patients with
NSCLC who had detectable KRAS mutations were re-
sistant to the treatment with TKIs and showed contin-
ued disease progression [1]. In addition, multiple studies
have demonstrated that tumors with activating KRAS
exon 1 mutations at G12X and G13X are associated witha lack of response to erlotinib and gefitinib (Table 1)
[17,66]. Notably, resistance to erlotinib does not appear
to be modulated by specific subtypes of activating KRAS
mutations, unlike the variable erlotinib sensitivities in-
curred by different EGFR mutations [67,68]. Granted,
while most of the evidence supports that KRAS muta-
tions grant resistance to EGFR-targeted TKIs, some
debate remains concerning the prognostic value of the
KRAS genotype on TKI treatment of NSCLC. This is
especially true given that in rare cases, patients with
KRAS mutations still respond to erlotinib [66,69]. Al-
though KRAS mutations are generally thought of as
mutually exclusive to EGFR mutations, overexpression
of (wt)-EGFR appears to be associated with a response
to erlotinib in these patients with KRAS mutants. This
could explain the atypical drug sensitivity exhibited by
these patients [1,66,69].
With respect to cetuximab for the treatment of colo-
rectal cancer, the negative prognostic value of KRAS mu-
tations is rigorously defined and is similar to the lack of
a response to erlotinib in KRAS-mutant patients with
NSCLC [15]. However, current evidence suggests that
KRAS mutations in patients with NSCLC do not neces-
sarily predict a poor response to cetuximab treatment
[16,68]. Instead of contradicting the importance of KRAS
variability in the treatment of NSCLC, the different
prognostic values of KRAS mutations in colorectal cancer
versus NSCLC only confirm the need to determine how
non-EGFR genetic variations affect the outcome of cetuxi-
mab treatment. For example, one convincing explanation
for the variable responses to cetuximab in patients with
KRAS-mutant colorectal cancer compared with patients
with KRAS-mutant NSCLC is that the KRAS mutations
found in each cohort are different and could thus elicit
variable protein-level effects on the structure and function
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of KRAS-activating G > T DNA transversions were found
at codon 12 of the KRAS gene in patients with NSCLC
compared with those found in patients with colorectal
cancer [68,70]. This might be due to the association of
such DNA transversion events with tobacco-related car-
cinogens [16,68,70]. The KRAS transversion mutations in
patients with NSCLC correspond to a greater frequency of
the G12C variant compared with the more predominant
G12D variant found in patients with colorectal cancer
[68]. Interestingly, recent findings have shown that in the
setting of colorectal cancer, at least 12 subtypes of KRAS
mutations across codons 12 and 13 associate with variable
yet negative efficacy of cetuximab [68,71]. An understand-
ing of what the different KRAS mutations are in NSCLC
and how they modulate the efficacy of cetuximab could
perhaps reveal similar subsets of KRAS mutations with
specific predictive value to treatment options of NSCLC.
If KRAS mutations are the most predominant genetic
alterations in the MAPK pathway that influence the effi-
cacy of EGFR-targeted therapies, then variation in the
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha (PIK3CA) is perhaps the corresponding gen-
etic abnormality in the downstream portion of the PI3K/
AKT pathway (Table 1) [1]. PIK3CA encodes the p110α
subunit of PI3K and is thus an integral part of the PI3K/
AKT signaling pathway (Figure 1) [1,31]. Previous evi-
dence has shown that PIK3CA mutations frequently
co-exist with EGFR mutations in NSCLC and that these
mutations could be predictive of reduced sensitivity to
TKIs (Table 1) [1,72-74]. Two of the most frequent mu-
tations in the helical domain of PIK3CA, E542K and
E545K, as well as one mutation in the kinase domain,
H1047R, are known to activate the p110α subunit and
to stimulate oncogenic signaling via the PI3K/AKT
pathway (Table 1) [73,75]. Notably, when such activat-
ing PIK3CA mutations are introduced into EGFR-mu-
tant lung cancer cells, they impart a partial resistance to
TKIs (Table 1) [73-76]. Interestingly, while this in vitro
association between PI3KC mutations and enhanced re-
sistance to EGFR-targeted TKIs has yet to be replicated
in the clinic in patients with NSCLC, one recent study
confirmed the high frequency of co-mutations of PI3KC
and EGFR in patients with NSCLC [72]. The same study
also found that the status of PI3KC mutations was a
negative prognostic indicator for survival in patients
with (wt)-EGFR and (wt)-KRAS subtypes [72]. More-
over, although limited experimental data are available to
explore the exact prognostic value of PIK3CA muta-
tions on the efficacy of cetuximab in NSCLC, activating
PIK3CA mutations in only the p110α catalytic domain,
and not in the helical domain, appear to grant similar
resistance to cetuximab in colorectal cancer cohorts
(Table 1) [77]. Moreover, other studies involving humanhead and neck cancer cell lines found that treatment
with either a PI3K inhibitor or a dual PI3K/mTOR
inhibitor enhances the sensitivity of cancer cells to
cetuximab in vitro and in vivo [78,79]. Thus, PI3K
mutations may contribute to the reduced efficacy of
erlotinib and cetuximab in specific subtypes of cancer
cells; however, further investigation is needed to con-
firm these associations in the clinical setting of NSCLC.
Given the important regulatory role of PTEN in AKT
activation (Figure 1), it is not surprising that PTEN is
another gene from the PI3K/AKT pathway with genetic
variations that are associated with the efficacy of EGFR-
targeted drugs [74]. Namely, one screen of various
NSCLC cell lines revealed that the homozygous loss of
PTEN was associated with the resistance to erlotinib in
the H1650 cell line [80]. In agreement with that report,
another study found that PTEN overexpression was
associated with prolonged survival after TKI treatment
in patients with NSCLC, which suggests that low ex-
pression or deletion of PTEN is associated with short-
ened survival in patients with NSCLC [81]. PTEN also
plays a role in the modulation of the response to cetu-
ximab. For instance, NSCLC cell lines were found to
acquire resistance to cetuximab, as well as to erlotinib,
as a result of enhanced PTEN instability and degrad-
ation [82]. This finding is notable in that it highlights
how, apart from the presence of a clear homozygous
PTEN deletion, PTEN genotyping may be less effective
than PTEN expression testing for the determination of
actual PTEN levels. Additional studies of the effects of
PTEN expression on the response to cetuximab in pa-
tients with metastatic colorectal cancer corroborate the
results in NSCLC in that the loss of PTEN expression
was found to be associated with poor overall survival
and drug resistance during cetuximab therapy [83,84].
Genetic variations in the NF-κB transcription factor
(Figure 1), a downstream member of the PI3K/AKT
pathway, also associate with specific responses to erlotinib
and cetuximab (Table 1) [1]. Specifically, the nuclear factor
of kappa light polypeptide gene enhancer in B-cells inhibi-
tor, alpha (NFKBIA) gene encodes the inhibitor of NF-κB
(IκBα) protein, which inhibits NF-κB activity by binding
NF-κB and confining it to the cytoplasm [1,85,86]. Strong
evidence supports that the knockdown of NFKBIA confers
partial resistance to erlotinib in lung cancer cell lines
through elevated levels of NF-κB and that this resistance
can be reversed by the inhibition of NF-κB or by the over-
expression of NFKBIA (Table 1) [1,87]. It was also demon-
strated that NFKBIA expression is a successful prognostic
biomarker for patients with EGFR-mutant NSCLC who
are treated with erlotinib and that low NFKBIA expression
is predictive of poor progression-free survival and overall
survival [1,87]. Notably, NFKBIA silencing is also found
far more frequently in patients with NSCLC who lack
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NSCLC, which suggests that such downstream activation
of the PI3K/AKT pathway can bypass the need for muta-
tions in upstream driver proteins during carcinogenesis
[85]. However, the mechanism that surrounds the variable
expression of NFKBIA has not been extensively studied.
Further support for the importance of NF-κB comes from
studies on astrocyte elevated gene-1 (AEG-1), an oncogene
that can increase NF-κB activity by activating the IκB kin-
ase (IKK), a protein that functions to destabilize IκBα
(Table 1) [1]. Patients with NSCLC whose tumors express
higher levels of AEG-1 appear to have poorer outcomes
than those with lower levels of AEG-1 after treatment with
TKIs, which suggests that genetic variations in AEG-1
could alter EGFR-targeted drug response in a similar fash-
ion to NFKBIA (Table 1) [1]. With respect to cetuximab,
while no specific evidence links genetic variations in NF-
κB or NFKBIA with drug efficacy on NSCLC, patients with
colorectal cancer whose tumors are negative for NF-κB
expression have a positive predictive response to cetuxi-
mab and a longer overall survival compared with patients
whose tumors are positive for NF-κB expression; the re-
sults were similar after erlotinib treatment in patients with
NSCLC (Table 1) [1,88].
Pharmacogenomics beyond EGFR: Non-EGFR RTKs
Just as genetic variations in the members of the EGFR
signaling pathway can bypass EGFR inhibition when
downstream effectors of EGFR are activated, mutations
in, or the overexpression of, non-EGFR RTKs can also
thwart the efficacy of EGFR-targeted agents via the acti-
vation of parallel signaling pathways. While the term
“parallel” is used to signify that a different RTK initiates
the signaling cascade, it is important to emphasize that
almost all RTKs function to activate the same small
number of central pathways (Figure 1) [29]. Therefore,
downstream of RTK activation, these parallel pathways
merge with the previously described pathways down-
stream of EGFR (Figure 1). Significantly, there are only
58 known RTKs among the 90 tyrosine kinases in the
human genome [19,89]. Given the redundancy of the
pathways downstream of activation, aberrant activation
of any other RTKs could foreseeably hinder a patient’s
response to erlotinib or cetuximab. This can therefore
provide a mechanism for both primary and acquired
resistance to these EGFR-targeted agents.
EGFR-targeted therapies in NSCLC have been linked
to genetic abnormalities in the MET gene, which en-
codes the MET protein or hepatocyte growth factor
receptor (HGFR), an RTK that recognizes the hepatocyte
growth factor (HGF) ligand [90]. In lung cancer, various
mutations in both the juxtamembrane domain and the
extracellular domains of MET, along with MET amplifi-
cation, are known to activate the receptor and stimulatethe PI3K/AKT signaling [91]. For instance, one study
found that increased MET copy number and MET over-
expression are negative prognostic factors for surgically
resected NSCLC (Table 1) [1,92]. In addition, MET gene
amplification and overexpression were found to be asso-
ciated with resistance of NSCLC cell lines to both erloti-
nib and gefitinib (Table 1) [93]. MET activation via HGF
ligand stimulation has also been shown to induce resist-
ance to EGFR-targeted TKIs even in the presence of
activating EGFR mutations (Table 1) [94]. Notably, gene
amplification of MET has been identified in up to 20%
of EGFR-mutant tumors that have been pretreated with
EGFR-targeted TKIs (Table 1). This suggests a role for
MET in the mediation of acquired resistance to these
drugs since MET amplification was rarely concomitant
with the common resistance-granting T790M EGFR mu-
tation [1,76,91,95,96]. Furthermore, one study detailed a
mechanism for such MET-mediated resistance by show-
ing that an EGFR TKI-sensitive lung cancer cell line can
develop resistance to gefitinib as a result of MET ampli-
fication via human epidermal growth factor receptor 3
(HER3)-dependent activation of PI3K (Table 1) [97].
Similarly, while the associations between cetuximab and
MET are currently limited to the setting of colorectal
cancer, MET amplification and activation were associated
with acquired resistance to cetuximab in treated patients,
and cetuximab-induced MET activation was found to
contribute to cetuximab resistance in certain colon
cancer cell lines (Table 1) [98,99].
Beyond its role in the modulation of overactive MET
signaling, HER3, a kinase-impaired RTK in the EGFR
family, can form active heterodimers with other members
of the EGFR family, namely EGFR and human epidermal
growth factor receptor 2 (HER2) [1,100]. It thus stands to
reason that HER3 expression patterns and mutation status
could impact the efficacy of therapies based on EGFR in-
hibition. Indeed, one study showed elevated levels of not
only MET but also HER2 and HER3 in cells that devel-
oped an acquired resistance to cetuximab [101]. The
authors propose that cetuximab treatment induces the up-
regulation of EGFR, which allows EGFR to form heterodi-
mers with HER3, HER2, and MET. This allows for the
maintenance of downstream EGFR signaling despite the
inhibition of EGFR homodimers [101]. The same study
further supports such a heterodimer-mediated mechanism
of resistance by demonstrating strong anti-proliferative
effects when these cancer cells were treated with both an
inhibitor of HER2/3 heterodimerization and cetuximab,
which suggests that HER2/3 heterodimers also help me-
diate cetuximab resistance in an EGFR-dependent man-
ner (Table 1) [101]. Given that HER2 is the preferred
dimerization partner of HER3 and that HER2/3 hete-
rodimers are more active and have greater oncogenic
potential than other dimers of the EGFR family, it is
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once both HER2 and HER3 are recruited to the mem-
brane by EGFR [102]. Therefore, such findings detail one
method, similar to those described for MET-mediated
resistance, by which cells can evade EGFR inhibition from
cetuximab. This is primarily accomplished by the re-
establishment of downstream tumorigenic signaling via
coordination with alternative RTKs.
The trend of up-regulated RTK activity that modulates
resistance to EGFR-targeted therapies is also observed
with HER2. For example, enhanced copy number of the
HER2 gene is associated with increased resistance to
both erlotinib and cetuximab (Table 1) [103,104]. More-
over, activating HER2 mutations are similarly associated
with poor response to erlotinib, even when they are con-
current with EGFR-sensitizing mutations (Table 1) [103].
Such mutations are typically found in exons 18–21 of
HER2 and alter the tyrosine kinase domain, which acti-
vates the receptor in the absence of ligand [103]. The
most common HER2 mutation is a 12-bp insertion at
exon 20, codon 776, which duplicates the amino acid se-
quence YVMA (HERYVMA) and thereby alters the HER2
ATP-binding pocket [103]. HERYVMA can activate EGFR in
the absence of EGFR ligands to bypass sensitivity to erloti-
nib and other EGFR-specific TKIs (Table 1) [103]. However,
because mutant HER2 compensates for EGFR inhibition in
cells that harbor HERYVMA, these cells are instead sensitive
to HER2 and dual HER2/EGFR inhibitors, which suggests
alternative therapeutic approaches for individuals with
NSCLC who harbor mutations in HER2 [103].
Our review focuses on parallel pathways that involve
MET, HER2, and HER3; however, other RTKs activate
the same downstream signaling cascades and thus could
also mediate responses to EGFR inhibition. Namely, the
vascular endothelial growth factor receptor (VEGFR), the
fibroblast growth factor receptor (FGFR), the platelet-
derived growth factor receptor (PDGFR), the AXL/UFO
receptor tyrosine kinase, the insulin-like growth factor 1
receptor (IGF1R), and still other RTKs similarly appear to
contribute to the observed resistance to EGFR inhibition
in NSCLC [105-109]. Nevertheless, our summarized find-
ings highlight the clinical value of the assessment of the
genetic variation in RTKs beyond EGFR that have the
potential to activate oncogenic pathways despite the pres-
ence of EGFR inhibitors. Our findings also emphasize
mechanisms of both primary and acquired resistance;
specifically, mutations or aberrations in other RTKs can
exist concurrently with EGFR mutations and can even be
present prior to EGFR-targeted therapy.
Discussion and conclusions
Focused pharmacogenomics research has discovered much
about EGFR and how EGFR mutations and expression can
guide EGFR-targeted treatment options in patients withNSCLC. The genetic variations in EGFR, however, are
unable to accurately predict drug responses to EGFR-
targeted agents for all patients with hyperactive EGFR
signaling, particularly during treatment with erlotinib
and cetuximab (Table 1). In patients with mutant EGFR,
for instance, EGFR mutations alone cannot account for
all of the observed primary drug resistance in NSCLC
patient groups. Therefore, we need to gain a better
understanding of why these patients with hyperactive
EGFR signaling have such variable responses to EGFR-
targeted therapies by designing studies to explore vari-
ation in other non-EGFR genes. While we have primarily
focused on somatic mutations and the differences in
protein expression beyond EGFR that cause primary
drug resistance to EGFR-targeted therapies, our findings
extend beyond primary drug resistance; namely, the
same genetic variation that is detailed in Table 1 might
help to explain the rampant acquired resistance to EGFR-
targeted agents that quickly follows an initial therapeutic
response in a majority of patients with NSCLC who are
treated with either erlotinib or cetuximab.
Deciphering the impact of mutations in, and variable
expression of, non-EGFR genes on EGFR-targeted NSCLC
treatment has significant and immediate clinical applica-
tions. At the prescriber level, one potential way to address
the variations in other RTKs or in downstream pathway
members of EGFR is to implement combination therapy.
Given the relatively small number of RTKs in the human
genome, more extensive genotyping can be performed to
screen for the common activating mutations in non-EGFR
RTKs. This would guide EGFR-targeted therapy choices
and options for combination therapy. Thorough RTK
screening could reveal mutant RTKs with oncogenic phe-
notypes that are silent or masked by the presence of the
more aggressive mutant EGFR. If mutations are found in
multiple RTKs, combination therapy approaches that
target all identified RTKs could be a powerful way to
minimize the risk of acquired resistance to EGFR-targeted
therapy.
For instance, EGFR-targeted inhibitors could be coupled
with inhibitors of KRAS, MET, PI3K, IKK, HER2, HER3,
or even with inhibitors of HER2/HER3 dimerization, to
anticipate resistance mediated by genetic abnormalities in
members of these downstream or parallel pathways. In
fact, several MET inhibitors are in phases II and III clinical
trials in the United States, and some are even being exam-
ined in combination therapy regimens along with EGFR
TKIs such as cetuximab [1,110,111]. The development of
additional dual-therapy approaches that investigate the
benefits of EGFR-targeted therapy in combination with
other RTK inhibitors and downstream pathway inhibitors
is in progress, and some combinatorial regimes show
clinical promise over EGFR inhibitors alone [112,113]. It is
important to note, however, that many of these new drugs
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when these drugs are released to the market, the cost,
adverse effects, and increased risk of drug-drug interac-
tions versus potential clinical benefit should be taken into
account during the process of deciding whether to admin-
ister combination therapy in the setting of NSCLC.
Even though the targeting of NSCLC with combin-
ation therapy is proving to be a powerful approach in
patients whose tumors are resistant to EGFR inhibition,
the mixed clinical results indicate that patient responses
to combination therapies can be just as varied as the
responses to EGFR inhibition. A more comprehensive
understanding of the genetic landscape of NSCLC sub-
types is thus needed to elucidate modulators of both
drug resistance and drug sensitivity to the various com-
binations of targeted therapies. Therefore, while the
pharmacogenomic associations listed in Table 1 provide
valuable insight into the treatment of NSCLC, additional
genetic factors will inevitably become important in the
future as specific, multifaceted therapies are tailored to
individual patients.
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